SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is facing intense scrutiny and volatility following an earnings report that featured a double-beat but was overshadowed by weak sales outlooks and ongoing struggles in the Chinese market. The community is deeply polarized, with many investors debating whether the stock's multi-year lows represent a generational buying opportunity or evidence of a brand in long-term decline amidst stiff competition and political headwinds.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MSTR is trending as market participants debate the stock's massive exposure to Bitcoin and the implications of its ongoing capital-raising strategy, which involves significant share dilution. Community discussions are highly polarized, pitting bulls who view recent price dips as a prime accumulation opportunity against bears who express deep skepticism regarding the firm's debt load and long-term sustainability.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is currently trending as investors focus on the upcoming Phase 3 VELA trial data presentation at the AAD annual meeting, which is expected to reinforce the stock's best-in-class potential for treating hidradenitis suppurativa. Community sentiment remains highly bullish, with active discussions centering on the potential for an imminent buyout and the belief that the stock is significantly undervalued by analysts relative to its long-term scientific merit.

Tema ETF Trust - Tema Space Innovators ETF

The newly launched Tema Space Innovators ETF ($NASA) is generating intense debate, with traders speculating it could mimic the high-volatility price action of other niche space-sector funds. While some investors are optimistic about its strategic exposure to industry leaders like SpaceX, critics are raising concerns regarding its low assets under management and the transparency of its underlying private holdings.

Ganymede

Ganymede is gaining traction as community members highlight its clean technical structure and consistent accumulation patterns. Investors are actively discussing the potential for significant momentum, viewing the current price action as a disciplined buildup phase.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing heightened community discussion as investors look toward the company's transition from R&D to production, with participants closely monitoring forward guidance for upcoming unit shipments and revenue. While some stakeholders express frustration over the timing of production milestones and lack of recent order disclosures, others are actively connecting POET's photonics technology to broader AI ecosystem shifts involving major hardware suppliers and hyperscalers.

Globalstar, Inc. engages in the provision of mobile satellite services. It offers voice and data communications services to the following markets: recreation and personal, government, public safety and disaster relief, oil and gas, maritime and fishing, natural resources, mining, and forestry, construction, utilities, and transportation. The company was founded in November 2003 and is headquartered in Covington, LA.

Globalstar Inc.

Globalstar is experiencing intense market focus as investors trade on speculative buyout rumors involving major technology and space players while closely tracking potential catalysts like the upcoming earnings report and regulatory approvals for next-generation satellite constellations. The community remains deeply divided, with some actively connecting dots between recent government contracts and strategic infrastructure partnerships, while others view the stock's lack of consistent volume as a sign of continued volatility in a highly speculative environment.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is currently a major focus for investors as the market anticipates the release of initial commercial sales data for its newly launched drug, Yartemlea. While the community is actively debating the stock's valuation, they are closely monitoring upcoming catalyst events, including potential European regulatory milestones and milestone payments from the ongoing partnership with Novo Nordisk.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is currently a major focus for market participants as they weigh a strong delivery pace against broader sector volatility driven by rising oil prices and geopolitical tensions. The community is sharply divided, with bulls pointing to the company's expanding infrastructure and production milestones as indicators of long-term value, while bears emphasize the stock's historical underperformance and ongoing concerns regarding profitability.

EchoStar Corp. engages in the design, development, and distribution of digital set-top boxes and products for direct-to-home satellite service providers. It operates through the following business segments: Pay-TV, Retail Wireless, and Broadband and Satellite Services. The Pay-TV segment business strategy is to be the best provider of video services in the United States by providing products with the best technology, outstanding customer service, and great value. The Retail Wireless segment offers Retail Wireless services as well as a competitive portfolio of wireless devices. The Broadband and Satellite Services segment business strategy is to maintain and improve leadership position and competitive advantage through development of technologies and services marketed to selected sectors within the consumer, enterprise and government markets globally. The company was founded by Charlie William Ergen, Candy Ergen, and James DeFranco in 1980 and is headquartered in Englewood, CO.

EchoStar Corp - Ordinary Shares - Class A

EchoStar Corp

EchoStar is currently trending as investors view the stock as a key proxy for gaining pre-IPO exposure to SpaceX, driven by the company's significant equity stake and ongoing spectrum monetization deals. Community discussion is focused on the potential for a massive valuation increase, with many closely tracking rumors of a secondary stock sale and the structural impacts of upcoming index inclusion.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Lifecore Biomedical (LFCR) to Release Earnings on Thursday

Lifecore Biomedical (NASDAQ:LFCR) will be releasing earnings after the market closes on Thursday, April 2. (View Earnings Report at...

Lifecore Biomedical (NASDAQ:LFCR) Earns Outperform Rating from Barrington Research

Barrington Research reiterated an "outperform" rating and issued a $5.50 price target on shares of Lifecore Biomedical in a research report on Tuesday...

Lifecore Biomedical CEO: Standalone CDMO Shift Complete, Utilization to Hit 60% by 2029

Lifecore Biomedical (NASDAQ:LFCR) CEO Paul Josephs told investors at a KeyBanc conference that the company has completed its transition into a standalone CDMO after divesting its former food...

Lifecore Biomedical, Inc. (NASDAQ:LFCR) Given Consensus Recommendation of "Hold" by Brokerages

Shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR - Get Free Report) have received a consensus recommendation of "Hold" from the five ratings firms that are covering the company, Marketbeat.com...

Lifecore Biomedical (NASDAQ:LFCR) Upgraded to Outperform at Barrington Research

Barrington Research upgraded Lifecore Biomedical from a "market perform" rating to an "outperform" rating and set a $5.50 price objective on the stock in a research note on Tuesday...

Lifecore Biomedical Q4 Earnings Call Highlights

Lifecore Biomedical (NASDAQ:LFCR) used its fiscal fourth-quarter earnings call to highlight revenue growth, improving margins, and continued cost reductions during its transition to a calendar-year...

Lifecore Biomedical (NASDAQ:LFCR) Stock Price Down 2.9% - Here's Why

Lifecore Biomedical (NASDAQ:LFCR) Stock Price Down 2.9% - Here's Why...

Lifecore Biomedical (NASDAQ:LFCR) Shares Up 1.4% - Should You Buy?

Lifecore Biomedical (NASDAQ:LFCR) Trading Up 1.4% - Here's Why...

HALPER SADEH LLC ENCOURAGES LIFECORE BIOMEDICAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

HALPER SADEH LLC ENCOURAGES LIFECORE BIOMEDICAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS HALPER SADEH LLC ENCOURAGES LIFECORE BIOMEDICAL, INC. SHAREHOLDERS TO CONTACT THE FIRM...

Lifecore Biomedical (NASDAQ:LFCR) Trading 2.8% Higher - Here's Why

Lifecore Biomedical (NASDAQ:LFCR) Stock Price Up 2.8% - Time to Buy...

Lifecore Biomedical, Inc. engages in the development and manufacturing of pharmaceuticals products and services. It focuses on selling products utilizing hyaluronan, a naturally occurring polysaccharide that is widely distributed in the extracellular matrix of connective tissues in both animals and humans, and non-HA products for medical use primarily in the Ophthalmic, Orthopedic and other markets. The company was founded by Otto Sartorius in 1965 and is headquartered in Chaska, MN.

Lifecore Biomedical Inc

Sprott Silver Miners & Physical Silver ETF ($SLVR)

Tradr 2x Long Innovation 100 Monthly ($MQQQ)

GraniteShares Autocallable NVDA ETF ($ANV)

Direxion Daily ASML Bull 2x ($ASMU)

The ultimate tool for the active trader. This award goes to the fund that helped traders master the market—whether by protecting against risks or jumping on the latest trends to capture quick wins.

Current Price	$3.72
Prev Close	$3.79
Open	$3.79
Dividend Yield	0.00%
50-Day Moving Average	$6.71
Beta	1.38
Avg. Volume	133,053.04
PE Ratio	-2.85

52-Week High	$8.98
52-Week Low	$3.63
Market Capitalization	$142.04M
EPS (Annual)	-$1.27
Price to Book	-9.82
Revenue Per Employee	$317,406.40

LFCR
Lifecore Biomedical Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LFCR News

LFCRLifecore Biomedical Inc